Indaptus Therapeutics sells 20.3 million shares in private placement for about $24.0 million
Indaptus Therapeutics agreed on September 8, 2026 to sell 20,338,974 shares of common stock to purchasers in a private placement for aggregate gross proceeds of about $24.0 million before offering expenses. The company plans to use the proceeds for working capital, research and development, and general corporate purposes, possibly including early-stage work on a neurotechnology device for sleep-related conditions. The shares are unregistered, and the company must later file a resale registration statement, which could add shares to the market.
Key points
- Shares sold: 20,338,974 shares of common stock at a price equal to the Nasdaq Minimum Price plus $0.015 per share
- Gross proceeds: approximately $24.0 million before offering expenses
- Closing: subject to customary conditions, no later than the fifteenth business day after September 8, 2026
- Shares were sold under Section 4(a)(2) and/or Regulation S and are subject to transfer restrictions
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.